#drug-pricing
#drug-pricing
[ follow ]
#trump-administration
Right-wing politics
fromThe American Conservative
1 week agoTrump Signs EO to Slash Drug Prices
Trump's executive order aims to equalize drug prices in the U.S. with the lowest prices in other countries.
The U.S. disproportionately funds global pharmaceutical profits, leading to higher drug prices domestically.
Right-wing politics
fromThe American Conservative
1 week agoTrump Signs EO to Slash Drug Prices
Trump's executive order aims to equalize drug prices in the U.S. with the lowest prices in other countries.
The U.S. disproportionately funds global pharmaceutical profits, leading to higher drug prices domestically.
Intellectual property law
fromIPWatchdog.com | Patents & Intellectual Property Law
1 month agoSenate Judiciary Committee Advances Pharma Patent Bills IP Advocates Say are Backed by Faulty Data
Senator Lee expressed concerns over proposed drug patent bills potentially undermining due process while addressing drug pricing issues.
#pharmaceuticals
Intellectual property law
fromIPWatchdog.com | Patents & Intellectual Property Law
1 month agoSenate Judiciary Committee to Consider Bills Targeting Pharma Patents and Pricing
Congress is reviewing drug patent regulation legislation based on refuted data.
The Center for American Principles warns against bills influenced by misleading drug market data.
Digital life
fromwww.nytimes.com
5 months agoBipartisan Lawmakers Seek to Break Up Giant Health Care Conglomerates
New bipartisan legislation seeks to prevent health insurers from owning pharmacies, targeting the monopolistic power of pharmacy benefit managers.
If enacted, this legislation could disrupt the current healthcare market dominated by a few conglomerates. The effort highlights ongoing concerns about drug pricing and transparency.
fromIPWatchdog.com | Patents & Intellectual Property Law
8 months agoChamber's GIPC Tells USPTO to Pivot on Coordination Plans with FDA
The U.S. Chamber of Commerce's Global Innovation Policy Center warns the USPTO against proposals for increased collaboration with the FDA, describing them as misguided 'coordination' efforts. These efforts are perceived as aimed at addressing perceived links between drug pricing and patent issues, which could complicate the patent examination process.
Privacy professionals
[ Load more ]